APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation.All publications related to hepatitis B reactivation with the use of...